Advertisement

QUAD SHOT Radiotherapy and Doublet Immunotherapy in the Management of Anal Mucosal Melanoma: A Case Series of Efficacy and Toxicity of a Novel Treatment Approach and a Review of the Literature

  • Martin J. Higgins
    Correspondence
    Address for correspondence: Martin J. Higgins, MB BCh BAO (Hons), FFRRCSI, Department of Radiation Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, 3000, Australia
    Affiliations
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • Ramin Alipour
    Affiliations
    Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • Kathy Pope
    Affiliations
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • Kim Ann Ung
    Affiliations
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • David L. Kok
    Affiliations
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • Margaret S-T Chua
    Affiliations
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
Published:March 13, 2022DOI:https://doi.org/10.1016/j.clcc.2022.03.001
      The improvements in survival seen in recent years with immunotherapy for advanced cutaneous melanoma have not translated to mucosal melanoma (MM), where outcomes remain poor. The quest to optimally harness the pro-immunogenic effects of RT in combination with immune checkpoint inhibitors (ICI) continues, especially in cancers with suboptimal response to ICI.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hodi FS
        • O'Day SJ
        • McDermott DF
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N Engl J Med. 2010; 363: 711-723
        • Ribas A
        • Puzanov I
        • Dummer R
        • et al.
        Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
        Lancet Oncol. 2015; 16: 908-918
        • Topalian SL
        • Sznol M
        • McDermott DF
        • et al.
        Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
        J Clin Oncol. 2014; 32: 1020-1030
        • SP D'Angelo
        • Larkin J
        • Sosman JA
        • et al.
        Efficacy and Safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis.
        J Clin Oncol. 2017; 35: 226-235
        • Larkin J
        • Chiarion-Sileni V
        • Gonzalez R
        • et al.
        Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
        N Engl J Med. 2015; 373: 23-34
        • Weber JS
        • D'Angelo SP
        • Minor D
        • et al.
        Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 375-384
        • Robert C
        • Long GV
        • Brady B
        • et al.
        Nivolumab in previously untreated melanoma without BRAF mutation.
        N Engl J Med. 2015; 372: 320-330
        • Wolchok JD
        • Kluger H
        • Callahan MK
        • et al.
        Nivolumab plus ipilimumab in advanced melanoma.
        N Engl J Med. 2013; 369: 122-133
        • Tas F
        • Keskin S
        • Karadeniz A
        • et al.
        Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
        Oncology. 2011; 81 (34863): 353-358
        • Temam S
        • Mamelle G
        • Marandas P
        • et al.
        Postoperative radiotherapy for primary mucosal melanoma of the head and neck.
        Cancer. 2005; 103: 313-319
        • Iddings DM
        • Fleisig AJ
        • Chen SL
        • Faries MB
        • Morton DL.
        Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?.
        Ann Surg Oncol. 2010; 17: 40-44
        • Verschraegen CF
        • Benjapibal M
        • Supakarapongkul W
        • et al.
        Vulvar melanoma at the M. D. Anderson cancer center: 25 years later.
        Int J Gynecol Cancer. 2001; 11: 359-364
        • Chang AE
        • Karnell LH
        • Menck HR.
        The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. the American college of surgeons commission on cancer and the American cancer society.
        Cancer. 1998; 83: 1664-1678
        • Hillenbrand A
        • Barth TF
        • Henne-Bruns D
        • Formentini A.
        Anorectal amelanotic melanoma.
        Colorectal Dis. 2008; 10: 612-615
        • Cagir B
        • Whiteford MH
        • Topham A
        • Rakinic J
        • Fry RD.
        Changing epidemiology of anorectal melanoma.
        Dis Colon Rectum. 1999; 42: 1203-1208
        • Nilsson P J
        • Ragnarsson-Olding B K
        Importance of clear resection margins in anorectal malignant melanoma.
        Br J Surg. 2010; 97: 98-103https://doi.org/10.1002/bjs.6784
        • Jutten E
        • Kruijff S
        • Francken AB
        • et al.
        Surgical treatment of anorectal melanoma: a systematic review and meta-analysis.
        BJS Open. 2021; 5 (PMID: 34958352): zrab107https://doi.org/10.1093/bjsopen/zrab107
        • Benlyazid A
        • Thariat J
        • Temam S
        • et al.
        Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study.
        Arch Otolaryngol Head Neck Surg. 2010; 136: 1219-1225
        • Lazarev S
        • Gupta V
        • Hu K
        • Harrison LB
        • Bakst R.
        Mucosal melanoma of the head and neck: a systematic review of the literature.
        Int J Radiat Oncol Biol Phys. 2014; 90: 1108-1118
        • Plavc G
        • But-Hadzic J
        • Anicin A
        • Lanisnik B
        • Didanovic V
        • Strojan P.
        Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013.
        Radiat Oncol. 2016; 11: 137
        • Gilligan D
        • Slevin NJ.
        Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses.
        Br J Radiol. 1991; 64: 1147-1150
        • Wu AJ
        • Gomez J
        • Zhung JE
        • et al.
        Radiotherapy after surgical resection for head and neck mucosal melanoma.
        Am J Clin Oncol. 2010; 33: 281-285
        • Wada H
        • Nemoto K
        • Ogawa Y
        • et al.
        A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan.
        Int J Radiat Oncol Biol Phys. 2004; 59: 495-500
        • Shi W.
        Radiation therapy for melanoma.
        in: Ward WH Farma JM Cutaneous Melanoma: Etiology and Therapy [Internet]. Codon Publications, Brisbane (AU)2017 (Chapter 8)
        • Formenti SC
        • Demaria S.
        Radiation therapy to convert the tumor into an in situ vaccine.
        Int J Radiat Oncol Biol Phys. 2012; 84: 879-880
        • Garnett CT
        • Palena C
        • Chakraborty M
        • Tsang KY
        • Schlom J
        • Hodge JW.
        Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
        Cancer Res. 2004; 64: 7985-7994
        • Goforth R
        • Salem AK
        • Zhu X
        • et al.
        Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
        Cancer Immunol Immunother. 2009; 58: 517-530
        • Chajon E
        • Castelli J
        • Marsiglia H
        • De Crevoisier R.
        The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership.
        Crit Rev Oncol/Hematol. 2017; 111: 124-132
        • Dewan MZ
        • Galloway AE
        • Kawashima N
        • et al.
        Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.
        Clin Cancer Res. 2009; 15: 5379-5388
        • Theurich S
        • Rothschild SI
        • Hoffmann M
        • et al.
        Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma.
        Cancer Immunol Res. 2016; 4: 744-754
        • Formenti SC.
        Optimizing dose per fraction: a new chapter in the story of the abscopal effect?.
        Int J Radiat Oncol Biol Phys. 2017; 99: 677-679
        • Postow MA
        • Callahan MK
        • Barker CA
        • et al.
        Immunologic correlates of the abscopal effect in a patient with melanoma.
        N Engl J Med. 2012; 366: 925-931
        • Corry J
        • Peters LJ
        • Costa ID
        • et al.
        The 'QUAD SHOT'–a phase II study of palliative radiotherapy for incurable head and neck cancer.
        Radiother Oncol. 2005; 77: 137-142
        • Lin MY
        • Kondalsamy-Chennakesavan S
        • Bernshaw D
        • Khaw P
        • Narayan K.
        Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes.
        J Gynecol Oncol. 2016; 27: e59
        • Basree M.
        • Mitchell D.
        • Dibs K.
        • et al.
        Initial experience with palliative “QUAD-SHOT” radiotherapy with concurrent and adjuvant PD-1 inhibitor for recurrent And/Or metastatic head and neck cancer.
        Int J Radiat Oncol Biol, Phys. 2020; 108 (Supplement p.e826)
        • Furney SJ
        • Turajlic S
        • Stamp G
        • et al.
        Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.
        J Pathol. 2013; 230: 261-269
        • Kim HJ
        • Chang JS
        • Roh MR
        • et al.
        Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients.
        Front. Oncol. 2019; 9: 835
        • Wallington DG
        • Rashid AS
        • Buchwald ZS
        • Sudmeier LJ
        • Khan MK.
        Complete and durable response after radiation therapy to primary tumor site of a patient with metastatic anorectal mucosal melanoma with oligoprogression on nivolumab.
        Adv Radiat Oncol. 2020; 5: 503-510
        • Wang WJ
        • Lee KD
        • Chen WY
        • et al.
        Combining hypofractionated radiation therapy with immunotherapy for anorectal malignant melanoma: a case report.
        Ther Radiol Oncol. 2019; 3: 1
        • Romano E
        • Honeychurch J
        • Illidge TM.
        Radiotherapy-immunotherapy combination: how will we bridge the gap between pre-clinical promise and effective clinical delivery?.
        Cancers (Basel). 2021; 13: 457
        • Xing D
        • Siva S
        • Hanna GG.
        The abscopal effect of stereotactic radiotherapy and immunotherapy: fool's gold or El dorado?.
        Clin Oncol (R Coll Radiol). 2019; 31: 432-443
        • Barker HE
        • Paget JT
        • Khan AA
        • Harrington KJ.
        The tumor microenvironment after radiotherapy: mechanisms of resistance and recurrence.
        Nat Rev Cancer. 2015; 15 (Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509): 409-425https://doi.org/10.1038/nrc3958
        • McBride S
        • Sherman E
        • Tsai CJ
        • et al.
        Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma.
        J Clin Oncol. 2021; 39: 30-37
        • Ratnayake G
        • Reinwald S
        • Shackleton M
        • et al.
        Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial.
        Int J Radiat Oncol Biol Phys. 2020; 108: 150-156
        • Akanda ZZ
        • Neeson PJ
        • John T
        • et al.
        A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
        Transl Lung Cancer Res. 2021; 10: 2766-2778
        • Menon H.
        • Chen D.
        • Ramapriyan R.
        • et al.
        Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.
        J Immunother Cancer. 2019; 7: 237
        • He K
        • Barsoumian HB
        • Sezen D
        • et al.
        Pulsed radiation therapy to improve systemic control of metastatic cancer.
        Front Oncol. 2021; 11737425
        • Barsoumian HB
        • Ramapriyan R
        • Younes AI
        • et al.
        Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
        J Immunother Cancer. 2020; 8e000537
        • Valkenburg KC
        • de Groot AE
        • Pienta KJ.
        Targeting the tumor stroma to improve cancer therapy.
        Nat Rev Clin Oncol. 2018; 15: 366-381
        • Patel RR
        • He K
        • Barsoumian HB
        • et al.
        High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial.
        Radiother Oncol. 2021; 162: 60-67
        • Tawbi HA
        • Forsyth PA
        • Algazi A
        • et al.
        Combined nivolumab and ipilimumab in melanoma metastatic to the brain.
        N Engl J Med. 2018; 379: 722-730https://doi.org/10.1056/NEJMoa1805453